Announcements
- MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
- MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
- MediWound to Participate in Two Upcoming Investor Conferences
- MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
- MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
- MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
- MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
- MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
- MediWound to Report Third Quarter 2023 Financial Results
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.10 |
---|---|
High | 10.10 |
Low | 10.00 |
Bid | 10.00 |
Offer | 10.60 |
Previous close | 10.00 |
Average volume | -- |
---|---|
Shares outstanding | 9.49m |
Free float | 7.05m |
P/E (TTM) | -- |
Market cap | 149.59m USD |
EPS (TTM) | -0.768 USD |
Data delayed at least 15 minutes, as of Dec 22 2022.
More ▼